Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMT103 in Postmenopausal Osteoporosis
NCT05278338Phase 2Unknown
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Apr 2022
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of narlumosbart in postmenopausal osteoporosis, sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Status: unknown.
02
Drugs
narlumosbart
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT05278338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05278338.